BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...stroke patients worldwide each year. Figure: NoNO selectively targets toxic NMDA receptor signaling in stroke NoNO...
...stroke,” said Tymianski. NoNO launched in 2003. Rather than use standard rat models of stroke, NoNO...
...secondary endpoints. Table: Clinical Results of NoNO Phase III Nerinetide Trial Phase III data from NoNO...
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

...peptides were not optimized for cell-specific targeting or intracellular localization. According to BioCentury’s BCIQ database, NoNO...
...and Xigen S.A. are the only two companies with HIV tat-based products in the clinic. NoNO’s...
...et de la Recherche Médicale (INSERM), Paris, France Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. NoNO...
BioCentury | Mar 3, 2017
Clinical News

NA-1: Ph III ESCAPE-NA-1 started

...evaluate 2.6 mg/kg IV NA-1 in about 1,120 patients who are candidates for endovascular revascularization. NoNo...
...index and mRS and mortality rate over 90 days Status: Phase III started Milestone: NA Julian Zhu NoNO...
BioCentury | Jan 7, 2016
Distillery Techniques

Techniques: Mouse model of intellectual disability involving non-POU domain containing octamer-binding (NONO; NMT55) mutations

Disease models GABA A receptor GABRA2 gephyrin (GPHN) non-POU domain containing octamer-binding NMT55 University of Zurich BC Staff...
BioCentury | Apr 7, 2014
Clinical News

Patrys preclinical data

...plans to start Phase I testing with the human IgM antibody that binds non-POU domain containing octamer-binding (NONO; NMT55...
BioCentury | Jan 20, 2014
Emerging Company Profile

Zocere: Stepping up in stroke

...activity in Phase II testing or earlier, including three that specifically target the NMDA pathway. NoNO...
...South San Francisco, Calif. Global Neurotech (GNT) Pharma Co. Ltd. , Yongin-si, South Korea NoNO...
BioCentury | Apr 29, 2013
Emerging Company Profile

Avilex: One-two pain punch

...with our dimeric approach," said CEO Robert Tansley. NA-1 , a monomeric PSD95 inhibitor from NoNO...
...animal models of pain. According to Tansley, NoNo's compound binds to only one PDZ domain. NoNo...
...higher affinity for PSD95 and a substantially longer half-life in human serum in vitro than NoNo's...
BioCentury | Mar 22, 2012
Tools & Techniques

Monkeys bridge the stroke gap

...Toronto-based NoNO Inc. has become the first company to show that macaque models have the potential...
...such models have largely precluded their use, said Michael Tymianski, cofounder, president and CEO of NoNO...
...the hospital's Toronto Western Research Institute . Previous Tymianski-led teams showed the neuroprotective effects of NoNO's...
BioCentury | Mar 8, 2012
Distillery Techniques

Technology: Disease models

...NoNo Inc., which licensed the findings, includes clinical trials of NA-1 to treat ischemic stroke. NoNO...
...hemorrhage. SciBX 5(10); doi:10.1038/scibx.2012.266 Published online March 8, 2012 Macaque models and NA-1 patented by NoNo...
BioCentury | Feb 8, 2010
Company News

CSL, Patrys deal

...lipoprotein (LDL) into cancer cells. PAT-LM1 is a preclinical human antibody that binds non-POU domain containing octamer-binding (NONO; NMT55...
Items per page:
1 - 10 of 12